|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/192 | (2006.01) |
| A61K 31/397 | (2006.01) | ||
| A61K 31/401 | (2006.01) | ||
| A61K 31/445 | (2006.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 37/06 | (2006.01) |
| (11) | Number of the document | 2379069 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09793546.4 |
| Date of filing the European patent application | 2009-12-21 | |
| (97) | Date of publication of the European application | 2011-10-26 |
| (45) | Date of publication and mention of the grant of the patent | 2015-03-04 |
| (46) | Date of publication of the claims translation | 2015-06-25 |
| (86) | Number | PCT/EP2009/067618 |
| Date | 2009-12-21 |
| (87) | Number | WO 2010/072703 |
| Date | 2010-07-01 |
| (30) | Number | Date | Country code |
| 139673 P | 2008-12-22 | US | |
| 09167209 | 2009-08-04 | EP |
| (72) |
LEGANGNEUX, Eric, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | S1P receptoriaus agonisto dozavimas |
| DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST |
| Payment date | Validity (years) | Amount | |
| 2025-11-21 | 17 | 347.00 EUR |
| 2026-12-21 |